Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Imaging of 89Zr-DFO-VRC01 in HIV-1 Infection
NCT03729752Phase 1Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Nov 2018
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial in human immunodeficiency virus type 1 infection (HIV-1) (3 arms), sponsored by University of California, San Francisco. Primary endpoints: Dosimetry of 89Zr-DFO-VRC01 at 120 hours and 89Zr-DFO-VRC01 temporal uptake at 120 hours. Started Nov 2018; status: recruiting.
02
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03729752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03729752.